**Question:** Digitoxin is used in A/E -

A. Heart failure
B. Atrial fibrillation
C. Thrombophlebitis
D. Electrolyte imbalances

**Core Concept:**
Digitoxin is a cardiac glycoside, a group of medications derived from the foxglove plant (Digitalis purpurea). It works by increasing the contractility of the heart muscle, decreasing the heart rate, and improving the heart's ability to pump blood efficiently. This is achieved through blocking the sodium-potassium ATPase pump in the cardiac cell membrane, leading to an increase in intracellular calcium and contractile force.

**Why the Correct Answer is Right:**
Digitoxin is used primarily in A/E (Atrial fibrillation and heart failure) due to its effects on cardiac contractility and rate control. In atrial fibrillation, digitoxin helps to stabilize the electrical activity of the heart, reducing the risk of thrombus formation and embolization. In heart failure, it improves cardiac output and reduces the workload on the heart, leading to symptom relief.

**Why Each Wrong Option is Incorrect:**
In C (Thrombophlebitis), digitoxin is not indicated as it does not directly address the cause of the problem (inflammation and thrombus formation in deep vein thrombosis) and may even worsen the condition by promoting thrombus formation.

In D (Electrolyte imbalances), digitoxin is not typically used to correct electrolyte imbalances, as its primary action is on the cardiovascular system. Instead, other medications like diuretics are used for this purpose.

**Clinical Pearl:**
Digitoxin should be used cautiously in patients with impaired renal function, as its clearance is reduced and its toxicity is more likely to occur. Regular monitoring of renal function and serum digoxin levels is essential when prescribing digitoxin.

**Correct Answer:**
**Correct Answer: B. Atrial fibrillation**

Digitoxin is primarily used in the treatment of Atrial Fibrillation (AF) and Heart failure (HF). In AF, it helps in stabilizing the electrical activity of the heart, reducing the risk of thrombus formation and embolization. In HF, digitoxin improves cardiac contractility and reduces the workload on the heart, leading to symptom relief.

In AF, the primary action of digitoxin is to inhibit the sodium-potassium pump in the cardiac myocyte, leading to the stabilization of the cardiac electrical activity. This results in a reduction of arrhythmias like AF, and hence, helps in preventing thrombus formation and embolization.

In HF, digitoxin acts by inhibiting the sodium-potassium pump in the cardiac myocyte, leading to an increase in contractility and cardiac output, thus reducing the workload on the heart and relieving symptoms.

Digoxin, another cardiac glycoside closely related to digitoxin, is used to treat AF and HF due to its pharmacological similarities. However, the distinction between the two is crucial, as they can act similarly, but have different pharmacokinetic properties and side